Filtered By:
Therapy: Cardiac Resynchronization Therapy

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 150 results found since Jan 2013.

Age-Dependence of Flow Homeostasis in the Left Ventricle
Conclusions: In average, blood spends 1 to 3 beats inside the LV with very low shear stress rates. The apical region is the most prone to blood stasis, particularly in mid-aged adults. The washout of blood in the normal LV is age-dependent due to physiological changes in the degree of apical penetration of the filling waves. Introduction Cardioembolic stroke is a major source of mortality and disability worldwide and blood stasis one of its major determinants (Adams et al., 1986). Left ventricular (LV) function has evolved to maximize mechanical efficiency and ensure organ perfusion at a low cost of energy and fill...
Source: Frontiers in Physiology - April 25, 2019 Category: Physiology Source Type: research

VVI Pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers
ConclusionIn patients without reduced LVEF or prolonged QRS duration who would be eligible for LP, DDDR and VVIR pacing demonstrated similar rates of death, stroke or heart failure hospitalization; however, VVIR pacing significantly increased the risk of AF development.This article is protected by copyright. All rights reserved
Source: Pacing and Clinical Electrophysiology : PACE - October 21, 2020 Category: Cardiology Authors: Zak Loring, Rebecca North, Anne S. Hellkamp, Brett D. Atwater, Camille G. Frazier ‐Mills, Kevin P. Jackson, Sean D. Pokorney, Gervasio A. Lamas, Jonathan P. Piccini Tags: DEVICES Source Type: research

VVI pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers
ConclusionIn patients without reduced LVEF or prolonged QRSd who would be eligible for LP, DDDR, and VVIR pacing demonstrated similar rates of death, stroke or HF hospitalization; however, VVIR pacing significantly increased the risk of AF development.
Source: Pacing and Clinical Electrophysiology : PACE - November 5, 2020 Category: Cardiology Authors: Zak Loring, Rebecca North, Anne S. Hellkamp, Brett D. Atwater, Camille G. Frazier ‐Mills, Kevin P. Jackson, Sean D. Pokorney, Gervasio A. Lamas, Jonathan P. Piccini Tags: DEVICES Source Type: research

Multipoint left ventricular pacing improves acute hemodynamic response assessed with pressure-volume loops in cardiac resynchronization therapy patients
Backgound: Conventional cardiac resynchronization therapy (CRT) improves acute cardiac hemodynamics.Objective: To investigate if CRT with multipoint left ventricular (LV) pacing in a single coronary sinus branch (MultiPoint Pacing [MPP], St Jude Medical, Sylmar, CA) can offer further hemodynamic benefits to patients.Methods: Forty-four consecutive patients (80% men, New York Heart Association III, end-systolic volume 180 ± 77 mL, ejection fraction 27% ± 6%, and QRS duration 152 ± 17 ms) receiving a CRT device implant (Unify Quadra MP or Quadra Assura MP and Quartet LV lead, St Jude Medical) underwent intraoperative asse...
Source: Heart Rhythm - December 2, 2013 Category: Cardiology Authors: Carlo Pappone, Žarko Ćalović, Gabriele Vicedomini, Amarild Cuko, Luke C. McSpadden, Kyungmoo Ryu, Enrico Romano, Massimo Saviano, Mario Baldi, Alessia Pappone, Cristiano Ciaccio, Luigi Giannelli, Bogdan Ionescu, Andrea Petretta, Raffaele Vitale, Angeli Tags: Devices Source Type: research

Feasibility of a novel atrioventricular delay optimization method using transmitral and pulmonary venous flow in patients with sequential ventricular pacing or cardiac resynchronization therapy
Conclusions AV delay optimization using TMF and PV flow was feasible. Usefulness of this method requires further investigation with a larger study population.
Source: Journal of Echocardiography - December 19, 2014 Category: Cardiology Source Type: research

MassDevice.com +3 | The top 3 medtech stories for November 24, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Ocular Therapeutix launches another pivotal for Dextenza eye drug-device combo Ocular Therapeutix said today that it launched another pivotal trial for its Dextenza drug-device combination, its 2nd study of the treatment for an allergic conjunctivitis indication. Bedford, Mass.-based Ocular Th...
Source: Mass Device - November 24, 2015 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 3 Source Type: news

HRS 2016 roundup: Leadless pacers at the fore
Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ), aiming to distinguish their respective leadless pacemaker offerings, presented new data last week in San Francisco at the Heart Rhythm Society’s annual meeting. St. Jude said a subset of data from the Leadless II trial showed that its Nanostim device was was successfully retrieved in 14 patients up to 3.2 years after implantation, with no serious adverse events. “We’ve now shown that for patients requiring device upgrades or new leadless pacing options, late retrievability – even up to 3 years – is possible with the Nanostim leadless pacemak...
Source: Mass Device - May 9, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management HRS 2016 Medtronic St. Jude Medical Source Type: news

MassDevice.com +5 | The top 5 medtech stories for November 14, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Final FDA rules clarify adverse event reporting for contract manufacturers The FDA last week issued final guidance for medical device companies on the requirements for reporting adverse events that walked back much of the burde...
Source: Mass Device - November 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

New insights from a computational model on the relation between pacing site and CRT response
Conclusions</div>In these model simulations, the best cardiac function was obtained when pacing the mid-basal LV lateral wall, because of fastest recruitment of LV activation. This study illustrates how computer modeling can shed new light on optimizing pacing therapies for CRT. The results from this study may help to design new clinical studies to further investigate the importance of the pacing site for CRT response.</span>
Source: Europace - December 22, 2016 Category: Cardiology Source Type: research

MassDevice.com +5 | The top 5 medtech stories for March 17, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. GlucoMe tackles connected diabetes management with acoustic data transmission The Centers for Disease Control & Prevention predict that by 2050, if current trends continue, 1 in 3 adults in the U.S. will have diabetes. The d...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Brad Perriello Tags: News Well Plus 5 Source Type: news

Endocardial left ventricular pacing for cardiac resynchronization: systematic review and meta-analysis
ConclusionLV endocardial pacing appears to be a viable technique when conventional lead placement is not possible. Response rates were heterogeneous but comparable with conventional CRT. There is likely to be a small increase over expected rates of stroke, although included patients were high risk.
Source: Europace - January 10, 2017 Category: Cardiology Source Type: research

Device-detected atrial fibrillation in a large remote-monitored cohort: implications for anticoagulation and need for new pathways of service delivery
ConclusionsDespite being intensively managed via RM software system incorporating cues for anticoagulation, a substantial proportion of patients with increased stroke risk remained unanticoagulated after a device-detected AF episode of significant duration. These data highlight the need for improved clinical response pathways and an integrated care approach to RM.Trial registrationAustralian New Zealand Clinical Trial Registry: ACTRN12620001232921.Graphical Abstract
Source: Journal of Interventional Cardiac Electrophysiology - February 3, 2023 Category: Cardiology Source Type: research

Recent advances in management of atrial fibrillation in patients with heart failure
The objective of this review is to provide an overview of atrial fibrillation in HF, and the implications for management. Recent findings: At present there is no evidence that a rhythm control strategy may bring any long-term benefits in routine management of atrial fibrillation in HF. Recently, the procedure of pulmonary vein isolation has been shown to provide clinical and prognostic benefits in patients with atrial fibrillation and concomitant HF who remain symptomatic despite optimal medical therapy, including rate and rhythm control. A meta-analysis of patients with atrial fibrillation and symptomatic HF who had impla...
Source: Current Opinion in Cardiology - January 1, 2013 Category: Cardiology Tags: HEART FAILURE: Edited by Haissam Haddad Source Type: research

The Year in Review of Clinical Cardiac Electrophysiology
This past year saw multiple important advances in the field clinical cardiac electrophysiology. Seminal articles describing new anticoagulant drugs for stroke prevention in atrial fibrillation were published. New results that raise questions regarding the safety of dronedarone and several new promising techniques in AF ablation were described. Important articles that refine our understanding of the risk of sudden death among Wolff-Parkinson-White patients were published. In the basic and translational sciences, the application of gene therapy to the study and potential treatment of arrhythmias was described, whereas geneti...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - February 11, 2013 Category: Cardiology Source Type: research